Company / Capital Expenditures
Enliven Therapeutics, Inc. Capital Expenditures History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$44.0K
FY2024
5-year range
$12.0K / $612.0K
FY2020-FY2024
Trend
-70.5%
vs FY2023
Sector context
#176 of 194
Health Care
What the data says
Among 194 Health Care companies, Enliven Therapeutics, Inc. is in the bottom 9% for capital expenditures. Declined from $612,000 to $44,000 over the past 2 years.
Based on SEC 10-K filings.
$44,000 in FY2024 with a 5-year CAGR of -20.7%.
Declined from $612,000 to $44,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +54.2%
- 5-Year CAGR
- -20.7%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 194This company $44.0K Sector average $117.5M
▼
-100.0% below sector average
Key checks
Key Insights
- 5-year CAGR of -20.7%, indicating a declining trend.
- In FY2024, capital expenditures decreased 70.5% year-over-year.
- Ranks #176 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.84 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $44.0K | -70.5% |
| FY2023 | $149.0K | -75.7% |
| FY2022 | $612.0K | +5000.0% |
| FY2021 | $12.0K | -33.3% |
| FY2020 | $18.0K | -87.1% |
| FY2019 | $140.0K | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026